Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| (133 intermediate revisions by 4 users not shown) | |||
| Line 7: | Line 7: | ||
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | ||
| + | :* Conformance Checklists (refer to Appendix C in the Profile document - pg 42) | ||
| + | :* Assessment Procedures (refer to Section 4 in the Profile document - pg 30) | ||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
| − | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 | + | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] |
| + | |||
| + | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | ||
| + | |||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | *[[Media: | + | *[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | QIBA CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23 |
| + | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] | ||
| + | |||
| + | *[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]] | ||
| + | |||
| + | *[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]] | ||
| − | *[[Media: | + | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]] |
| − | * [[Media: | + | *[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]] |
| − | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT | + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]] |
| + | |||
| + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]] | ||
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | *[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | ||
| + | |||
| + | *[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]] | ||
| + | :*[[Media:QIBA_CTA_Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]] | ||
| + | |||
| + | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
| − | ''' | + | '''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']''' |
| + | |||
| + | *[[Media:QIBA_DCE-MRI_Profile-Stage_1-Public_Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''<span style="color:#00b300">Open until March 10, 2021</span>''') | ||
| + | |||
| + | *[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020) | ||
| + | |||
| + | *[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019) | ||
| − | *[[Media: | + | :*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019) |
| + | *[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017) | ||
| − | '''[[Comment Resolutions]] for Past Public Comments''' | + | '''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font> |
| − | ==Format for Citing Profiles== | + | |
| + | ====Format for Citing Profiles==== | ||
Cite QIBA Profile documents as: | Cite QIBA Profile documents as: | ||
| − | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. | + | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL'' |
Example: | Example: | ||
| − | : QIBA | + | : QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles |
| − | ==Statements of Endorsement== | + | ====Statements of Endorsement==== |
*[[Industry]] | *[[Industry]] | ||
*[[Clinical Sites]] | *[[Clinical Sites]] | ||
*[[Additional letters of support can be found here]] | *[[Additional letters of support can be found here]] | ||
| − | + | ====See Also==== | |
| − | ==See Also== | ||
*[[How to use QIBA Profiles]] | *[[How to use QIBA Profiles]] | ||
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | *[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | ||
Revision as of 17:48, 9 December 2020
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
- Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
- Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
Stage 2: Consensus Profiles
- QIBA CT Lung Density Profile_09.04.2020, clean version (Contains Conformance Checklist, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
Please submit comments using the online form
- MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12 (Open until March 10, 2021)
- MR MSK cartilage for joint disease 2020-05-18 (closed on October 29, 2020)
- US Shear Wave Speed for Liver Fibrosis 2019-10-21 (closed on December 18, 2019)
- Appendix E: SWS Checklists, 2019-10-21 (closed on December 18, 2019)
- fMRI for Sensorimotor Mapping 2017-06-19 (closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)